Charles Hoskinson, founder of Cardano (ADA), has intensified the rivalry with Ethereum (ETH) and made other key comments in his recent Ask Me Anything (AMA) session on Sunday.Charles Hoskinson, founder of Cardano (ADA), has intensified the rivalry with Ethereum (ETH) and made other key comments in his recent Ask Me Anything (AMA) session on Sunday.

Cardano founder intensifies rivalry with Ethereum amid ADA's bearish streak

  • Charles Hoskinson promotes Cardano over Ethereum in a surprise AMA session on Sunday. 
  • Cardano’s ADA token extends the downtrend for the fourth consecutive day, risking a drop below $0.80. 
  • The on-chain data reflects Ethereum’s superiority over Cardano.

Charles Hoskinson, founder of Cardano (ADA), has intensified the rivalry with Ethereum (ETH) and made other key comments in his recent Ask Me Anything (AMA) session on Sunday. Ethereum, the largest altcoin by market capitalization of $532 billion, outpaces Cardano by a huge margin, which has a valuation of $28 billion. Furthermore, the on-chain data puts Ethereum on a pedestal far higher than Cardano, reflecting its larger adoption.

Key comments of Charles Hoskinson

Charles Hoskinson, one of the co-founders of Ethereum, has picked sides with his brainchild, Cardano. In an AMA session on Sunday, Hoskinson responded with “I want Cardano to win” against Ethereum, while urging developers to build more on the Cardano blockchain. 

The founder also tapped into the Glacier update, which will introduce Hydra protocol, Cardano smart contracts, and the Midnight token. This will likely increase the decentralized finance (DeFi) share of Cardano. 

Furthermore, Hoskinson shared an experience with Sergey Nazarov, the founder of Chainlink (LINK), who asked him for too high a price for integration. As per Hoskinson, “Segey is an extremely smart man that sees the future and knows he’s sitting on a golden egg.”

Cardano’s uphill battle with Ethereum

Ethereum, a well-established smart contract and DeFi powerhouse, holds a Total Value Locked (TVL) of $91.64 billion, representing the total on-chain asset value. This is significantly higher than Cardano’s total on-chain assets, worth $362 million, as the blockchain struggles to implement smart contract functionalities and decentralized Applications (dApps). 

Furthermore, the transaction over the two blockchains highlights the huge difference in user adoption. Chainspect data shows 1.46 million daily transactions on Ethereum compared to 27,329 transactions on Cardano. 

Cardano vs Ethereum transaction volume. Source: Chainspect

Transactions occurring per second (TPS) in Ethereum are at 17.78 transactions, outpacing Cardano's 0.27 TPS. Fundamentally, Ethereum holds the ground with the maximum theoretical TPS of 119 compared to Cardano’s 18 TPS. 

Cardano vs Ethereum scalability. Source: Chainspect

To compete with Ethereum, the upcoming Glacier update in Cardano could provide the initial boost to reshape its DeFi space and increase its adoption. 

Cardano risks further losses 

Cardano edges lower by 1% at press time on Monday, extending the losses for the fourth consecutive day. The downtrend in ADA steeply falls below the 50-day Exponential Moving Average (EMA) at $0.8126, targeting the 200-day EMA at $0.7426.

The momentum indicators on the daily chart indicate a bearish tilt as overhead pressure intensifies. A declining trend in the Relative Strength Index (RSI) crosses below the halfway line, reaching 44, indicating a steady decline in buying pressure. 

The Moving Average Convergence Divergence (MACD) and its signal line inch closer towards the zero line, indicating a rise in selling pressure.

ADA/USDT daily price chart.

Looking up, to reinforce a recovery run, Cardano should reclaim the 50-day EMA at $0.8126.


Market Opportunity
ME Logo
ME Price(ME)
$0.2162
$0.2162$0.2162
-3.09%
USD
ME (ME) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Over $145M Evaporates In Brutal Long Squeeze

Over $145M Evaporates In Brutal Long Squeeze

The post Over $145M Evaporates In Brutal Long Squeeze appeared on BitcoinEthereumNews.com. Crypto Futures Liquidations: Over $145M Evaporates In Brutal Long Squeeze
Share
BitcoinEthereumNews2026/01/16 11:35
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Edges higher ahead of BoC-Fed policy outcome

Edges higher ahead of BoC-Fed policy outcome

The post Edges higher ahead of BoC-Fed policy outcome appeared on BitcoinEthereumNews.com. USD/CAD gains marginally to near 1.3760 ahead of monetary policy announcements by the Fed and the BoC. Both the Fed and the BoC are expected to lower interest rates. USD/CAD forms a Head and Shoulder chart pattern. The USD/CAD pair ticks up to near 1.3760 during the late European session on Wednesday. The Loonie pair gains marginally ahead of monetary policy outcomes by the Bank of Canada (BoC) and the Federal Reserve (Fed) during New York trading hours. Both the BoC and the Fed are expected to cut interest rates amid mounting labor market conditions in their respective economies. Inflationary pressures in the Canadian economy have cooled down, emerging as another reason behind the BoC’s dovish expectations. However, the Fed is expected to start the monetary-easing campaign despite the United States (US) inflation remaining higher. Investors will closely monitor press conferences from both Fed Chair Jerome Powell and BoC Governor Tiff Macklem to get cues about whether there will be more interest rate cuts in the remainder of the year. According to analysts from Barclays, the Fed’s latest median projections for interest rates are likely to call for three interest rate cuts by 2025. Ahead of the Fed’s monetary policy, the US Dollar Index (DXY), which tracks the Greenback’s value against six major currencies, holds onto Tuesday’s losses near 96.60. USD/CAD forms a Head and Shoulder chart pattern, which indicates a bearish reversal. The neckline of the above-mentioned chart pattern is plotted near 1.3715. The near-term trend of the pair remains bearish as it stays below the 20-day Exponential Moving Average (EMA), which trades around 1.3800. The 14-day Relative Strength Index (RSI) slides to near 40.00. A fresh bearish momentum would emerge if the RSI falls below that level. Going forward, the asset could slide towards the round level of…
Share
BitcoinEthereumNews2025/09/18 01:23